SI-BONE (SIBN) CEO Laura Francis sells 14,957 shares to cover RSU tax bill
SI-BONE, Inc.'s CEO, Laura Francis, sold 14,957 shares of common stock on May 18, 2026, to cover tax withholding obligations associated with vesting restricted stock units. These sales were non-discretionary, executed at weighted average prices around the mid-$14 range. Following the transactions, Francis directly holds 540,476 shares and indirectly holds 378,682 shares through a family trust, maintaining significant equity exposure in the company.
SI-BONE (SIBN) legal chief sells 3,726 shares in tax sell-to-cover
Michael A. Pisetsky, SI-BONE's SVP and Chief Legal Officer, sold 3,726 shares of common stock on May 18, 2026, for approximately $14.63 per share. These transactions were "sell to cover" sales to meet tax obligations from restricted stock unit vesting, not discretionary trades. Pisetsky still holds 1,395 shares from an employee stock purchase plan and 143,729 shares awaiting settlement from restricted stock units.
Tax-related SI-BONE (SIBN) CFO sale of 4,666 shares disclosed
Anshul Maheshwari, CFO of SI-BONE, Inc. (SIBN), sold 4,666 shares of common stock in two transactions at weighted average prices of $14.6545 and $14.7132 per share. These sales were explicitly identified as "sell to cover" transactions to meet tax withholding obligations for vested restricted stock units, not discretionary trades. Maheshwari retains a substantial equity position, including 183,921 shares issuable from outstanding restricted stock units and 1,395 shares acquired via an Employee Stock Purchase Plan.
Si-Bone CEO Laura Francis sells $220,000 in company stock
Laura Francis, CEO of SI-BONE, Inc., sold 14,957 shares of company stock worth $220,000 on May 18, 2026. These "sell to cover" transactions were made to satisfy tax obligations related to restricted stock units, not as discretionary trades. Following the sales, Ms. Francis continues to hold significant direct and indirect shares in the company, which recently reported strong Q1 2026 financial results, beating EPS forecasts despite slightly missing revenue.
Earnings call transcript: Si-Bone Q1 2026 beats EPS forecast, stock rises
SI-BONE, Inc. reported strong first-quarter 2026 financial results, with EPS of -$0.10 significantly beating the forecast of -$0.19, and revenue reaching $52.6 million. The company's stock rose in aftermarket trading, reflecting investor confidence fueled by an 11.2% year-over-year revenue growth, high gross margins, and strategic initiatives in product innovation and market expansion. Si-Bone also provided an optimistic outlook, raising its full-year guidance and highlighting potential tailwinds from new product launches and favorable reimbursement changes.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. (Nasdaq: SIBN) announced its financial results for the first quarter of 2026, reporting worldwide revenue of $52.6 million, an 11.2% increase year-over-year, and improved net loss and adjusted EBITDA. The company also raised its full-year 2026 revenue guidance to between $230 million and $233 million, reflecting confidence in its product pipeline and market expansion. Key operational highlights included growth in active U.S. physicians and international launches of new products.
SI-BONE stock (US8255921098): Q1 beat and raised FY26 guidance drive gains
SI-BONE Inc. reported better-than-expected Q1 2026 financial results and raised its full-year 2026 sales guidance, with the midpoint now exceeding consensus estimates. This positive news has driven the stock higher on the Nasdaq, reflecting increased investor confidence. The medical device company specializes in minimally invasive spine and sacroiliac joint fusion solutions, capitalizing on the growing demand for less invasive surgical techniques.
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
After SI-BONE Inc. released its Q1 results, analysts have updated their forecasts for 2026, predicting US$231.6m in revenue and narrower losses per share at US$0.43. Despite the improved sentiment regarding loss estimates, the average price target for the company has been trimmed by 5.4% to US$24.13, suggesting a more pessimistic outlook on its intrinsic value. The company is still expected to experience notable revenue growth, projected to outperform the broader medical equipment industry.
SI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedure
SI-BONE is projecting strong revenue growth for 2026, targeting $230 million to $233 million, driven by the expanding market for its iFuse and Granite systems. The company anticipates a significant boost from proposed new Medicare Severity Diagnosis Related Groups (MS-DRGs) by CMS, which could increase reimbursement for its Granite procedure by up to $50,000 per case, potentially enhancing its market penetration and financial performance.
SI-BONE, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SIBN) 2026-05-12
SI-BONE, Inc. has released its Q1 2026 earnings call presentation. The company reported an EPS of -$0.10, beating estimates by $0.09, and revenue of $52.59M, exceeding expectations by $1.43M with an 11.20% year-over-year increase. This presentation is provided in conjunction with their earnings call.
SI-BONE, Inc. (NASDAQ:SIBN) Q1 2026 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN) reported strong Q1 2026 results, beating earnings expectations with worldwide revenue growth of over 11%. The company raised its full-year revenue guidance to $230 million to $233 million, citing confidence in its strategic initiatives, including new product launches like Intra TI and the expansion of its pelvic trauma portfolio through a partnership with Smith & Nephew. A significant potential tailwind is the proposed new DRGs by CMS, which could increase reimbursement for spinal pelvic procedures using Granite, further establishing it as a standard of care.
Truist Lowers Price Target on SI-BONE to $18 From $20, Keeps Buy Rating Rating
Truist has lowered its price target for SI-BONE (SIBN) shares to $18 from $20, while maintaining a "Buy" rating on the medical device company. This adjustment comes despite SI-BONE's recent Q1 2026 earnings report, which indicated a narrower loss and increased revenue, alongside a raised 2026 revenue outlook. The article also notes other recent analyst actions and company news, including SI-BONE's presentation at a healthcare conference.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) reported a smaller-than-expected loss of $0.10 per share for Q1 2026, beating the Zacks Consensus Estimate of a $0.17 loss, and also exceeded revenue estimates with $52.59 million. Despite this, the stock has underperformed the S&P 500 this year, with a Zacks Rank #3 (Hold) indicating expected market-performances in the near future. The company operates within the Medical - Instruments industry, which is currently ranked in the top 44% of Zacks industries.
SI-BONE 1Q Loss/Shr 10c >SIBN
This article reports that SI-BONE (SIBN) recorded a Q1 loss per share of 10 cents. The ticker symbol for SI-BONE is SIBN.
Si-Bone: Q1 Earnings Snapshot
Si-Bone Inc. reported a first-quarter loss of $4.3 million, or 10 cents per share. The medical device company generated $52.6 million in revenue during the period and anticipates full-year revenue to be between $230 million and $233 million. This financial update was compiled using data from Zacks Investment Research.
[10-Q] SI-BONE, Inc. Quarterly Earnings Report
SI-BONE, Inc. has filed its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The company reported a net loss of $4.3 million for the quarter, an improvement from $6.5 million in the same period last year, with revenue increasing by 11.2% to $52.5 million driven by higher U.S. procedure volumes. SI-BONE highlights its focus on expanding solutions for compromised bone, physician engagement, employee experience, and operational efficiency, while also detailing its financial position, including cash and marketable securities of $144.7 million and outstanding debt of $35.6 million.
SI-BONE (NASDAQ: SIBN) lifts 2026 outlook after double-digit Q1 growth
SI-BONE, Inc. (NASDAQ: SIBN) reported strong first-quarter 2026 results, with worldwide revenue growing 11.2% to $52.6 million and a significant improvement in adjusted EBITDA to $2.5 million. Following this performance, the company raised its full-year 2026 revenue guidance to between $230 million and $233 million, implying 14-16% growth, and increased its gross margin expectation to approximately 79%. These results and increased outlook demonstrate the company's solid operational leverage and expanding market presence.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. announced strong financial results for the first quarter of 2026, reporting worldwide revenue growth of 11.2% to $52.6 million and a significant improvement in adjusted EBITDA to $2.5 million. The company also raised its full-year 2026 revenue guidance to between $230 million and $233 million, citing record physician engagement and successful new product launches. Key operational highlights included expanding international presence and a proposed CMS rule change that could positively impact reimbursement for complex spinal fusion procedures utilizing SI-BONE's products.
Si-Bone: Q1 Earnings Snapshot
Si-Bone Inc. (SIBN) reported a first-quarter loss of $4.3 million, or 10 cents per share. The medical device company, based in Santa Clara, California, announced revenues of $52.6 million for the period and projects full-year revenue to be between $230 million and $233 million. This information was generated using data from Zacks Investment Research.
Number of shareholders of SI-BONE, Inc. – SWB:2K3
This article provides the number of shareholders for SI-BONE, Inc., traded under the ticker SWB:2K3 on the Stuttgart Stock Exchange. The content appears to be a stub or data placeholder, focusing primarily on the company's financial overview and market information from TradingView. It also acknowledges the data providers involved.
First Light, Mathew Arens disclose 18% stake in SI-BONE (NASDAQ: SIBN)
First Light Asset Management, LLC and Mathew P. Arens have jointly reported a significant beneficial ownership stake in SI-BONE, Inc. (NASDAQ: SIBN). First Light now holds 18.02% of the company's shares, while Mr. Arens, who controls First Light and holds additional direct shares, has an attributable ownership of 18.36%. This Schedule 13G/A amendment indicates a passive investment, not an attempt to change corporate control.
Earnings Preview: Si-Bone to Report Financial Results Post-market on May 11
This article announces that Si-Bone (SIBN) is scheduled to release its financial results after the market closes on May 11. The article implies that this upcoming earnings report will be closely watched by investors and analysts.
SI-BONE (SIBN) director Dunn sells small stake to cover RSU taxes
SI-BONE, Inc. director Jeffrey W. Dunn sold 337 shares of common stock on May 4, 2026, at a weighted average price of $13.1508. This non-discretionary "sell to cover" transaction was solely to satisfy tax withholding obligations related to the vesting of restricted stock units. After the sale, Dunn directly holds 9,157 shares (including 8,675 RSU-issuable shares) and indirectly holds 80,591 shares through a living trust.
Price-Driven Insight from (SIBN) for Rule-Based Strategy
The article provides a price-driven analysis of Si-bone Inc. (NASDAQ: SIBN) for rule-based trading strategies, highlighting weak sentiment across all horizons supporting a short bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing weak signals across near-term, mid-term, and long-term horizons.
Hussman Strategic Advisors Inc. Purchases Shares of 84,000 SiBone $SIBN
Hussman Strategic Advisors Inc. acquired 84,000 shares of SiBone (NASDAQ:SIBN) in the fourth quarter, establishing a new stake valued at approximately $1.66 million, which represents a 0.19% ownership. This comes amid significant insider selling totaling $2.55 million over the past three months, reducing insider holdings to 4.0%. Despite insider sales, SiBone exceeded Q4 EPS estimates, and analysts maintain a "Moderate Buy" rating with a target price of $24.00.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 BofA Securities Healthcare Conference. Management will host a fireside chat on May 12, 2026, at 8:00 a.m. Pacific Time. Investors can register via a provided link or listen to the webcast on the company's website.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE (Nasdaq: SIBN) announced it will participate in the BofA Securities 2026 Healthcare Conference in Las Vegas, NV, on Tuesday, May 12, 2026. Management will host a fireside chat at 8:00 a.m. PT / 11:00 a.m. ET, with live audio available via webcast on the company’s investor relations page. The webcast will also be archived for at least 90 days for replay.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will host a fireside chat on May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. A live audio webcast will be available on the company’s website, with an archive available for replay for at least 90 days.
Impax Asset Management Group plc Has $23.66 Million Stock Holdings in SiBone $SIBN
Impax Asset Management Group plc increased its stake in SiBone (NASDAQ:SIBN) by 17.1% in the fourth quarter, bringing their total holdings to $23.66 million. Other institutional investors have also adjusted their positions in SiBone, with 98.11% of the stock owned by institutional investors and hedge funds. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for SiBone, with an average target price of $24.00.
BlackRock (SIBN) files Schedule 13G/A reporting 6.9% ownership of SI-BONE
BlackRock, Inc. has filed an amended Schedule 13G/A, disclosing a 6.9% beneficial ownership stake in SI-BONE, Inc., totaling 3,057,039 shares. The filing indicates BlackRock holds sole voting power over 2,997,105 shares and sole dispositive power over all 3,057,039 shares. This amendment, signed by Spencer Fleming, Managing Director, on April 24, 2026, details BlackRock's significant but passive investment in SI-BONE.
Needham maintains SI-BONE (SIBN) buy recommendation
Needham has reiterated its Buy recommendation for SI-BONE (SIBN). This indicates continued confidence from the analyst firm in the company's prospects.
(SIBN) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Si-bone Inc. (NASDAQ: SIBN) stock performance, noting near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It highlights an exceptional 65.3:1 risk-reward setup, targeting a 20.6% gain against a 0.3% risk. The analysis also details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles.
SI-BONE (NASDAQ: SIBN) sets 2026 virtual meeting, director and pay votes
SI-BONE (NASDAQ: SIBN) has announced its 2026 virtual annual meeting on June 4, 2026, where stockholders will vote on the re-election of Jeffrey W. Dunn and John G. Freund, M.D. as directors, the ratification of PricewaterhouseCoopers LLP as auditor, and an advisory vote on executive compensation. The company reported strong 2025 financial results, including worldwide revenue of $200.9 million (20% growth) and positive Adjusted EBITDA of $8.9 million. The executive compensation program for 2025 emphasizes pay-for-performance, with a significant portion of compensation tied to financial and operational goals, and includes both time-based and performance-based equity awards.
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced it will report its first-quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call for investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can register to listen to the webcast via the provided link or on the company's website, with an archive available for replay for at least 90 days.
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SI-BONE, Inc. announced it will report its first-quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for investors, with webcast details available on the company's website. SI-BONE is a global leader in procedural solutions for compromised bone, with a strong clinical evidence base.
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SI-BONE, Inc. announced it will release its first-quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a conference call, accessible via webcast, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results. SI-BONE specializes in developing procedural solutions for compromised bone, particularly in spinopelvic anatomy, leveraging its technology platform and extensive clinical evidence.
SI-BONE schedules May 11 earnings release, 4:30 p.m. ET call
SI-BONE (Nasdaq: SIBN) announced that it will report its first-quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day for investors and management. A webcast link is provided for registration, and the replay will be available for at least 90 days.
SiBone (NASDAQ:SIBN) Downgraded by Wall Street Zen to Hold
Wall Street Zen has downgraded SiBone (NASDAQ:SIBN) from a "buy" to a "hold" rating, despite the company beating Q4 EPS estimates with revenue of $56.35 million. SiBone remains unprofitable with a net margin of -9.41% and a market cap of approximately $622 million, trading around $14.09. Insiders have sold a significant number of shares recently, though institutional investors hold a large majority of the stock.
Truist Financial Maintains Si-Bone(SIBN.US) With Buy Rating, Cuts Target Price to $20
Truist Financial has reiterated its Buy rating for Si-Bone (SIBN.US), a medical device company. However, the firm has adjusted its price target for SIBN.US downward from $27 to $20.
SiBone (NASDAQ:SIBN) Stock Price Down 4.8% on Analyst Downgrade
SiBone (NASDAQ:SIBN) shares experienced a 4.8% drop after Truist Financial lowered its price target from $24 to $20, while still maintaining a "buy" rating. Despite the downgrade, analysts collectively hold a "Moderate Buy" consensus with an average price target of $24. Insider selling has been noted, but institutional ownership remains high, with several large funds increasing their positions.
Truist Financial Lowers SiBone (NASDAQ:SIBN) Price Target to $20.00
Truist Financial has lowered its price target for SiBone (NASDAQ:SIBN) from $24.00 to $20.00, while maintaining a "buy" rating, indicating a potential upside of 37.36%. Despite the lowered target, analyst sentiment remains largely positive with a "Moderate Buy" consensus. The article also highlights notable insider selling, with the CEO and other insiders selling off a significant number of shares recently.
Truist Cuts Price Target on SI-BONE to $20 From $24, Keeps Buy Rating
Truist has lowered its price target for SI-BONE (SIBN) to $20 from $24, while maintaining a "Buy" rating on the stock. This adjustment comes amidst other recent analyst activities, including new coverage from TD Cowen with a $21 price target and a previous price target adjustment by Truist Securities to $24 from $23. The article highlights SI-BONE's focus on minimally invasive surgical implant systems for sacropelvic disorders.
(SIBN) as a Liquidity Pulse for Institutional Tactics
Stock Traders Daily's AI models analyze Si-bone Inc. (NASDAQ: SIBN), indicating a near-term strong sentiment but a neutral mid and long-term outlook with a breakdown underway. The article provides three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. It also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
SI-BONE’s Long-Term Vision Takes Hold: Record Revenue Growth, Positive Adjusted EBITDA, and Expanding Innovation and Distribution
SI-BONE, Inc. reported record financial performance for 2025, achieving $200.9 million in worldwide revenue, a 20% year-over-year increase, and positive adjusted EBITDA. The company also expanded its product portfolio with the FDA clearance of iFuse INTRA Ti and entered a strategic distribution agreement with Smith+Nephew, positioning itself for continued growth and market expansion in 2026 with a favorable reimbursement environment.
Director Greg Hinckley adds 3,085 SI-BONE (SIBN) shares via options
SI-BONE, Inc. director Greg K. Hinckley exercised stock options to acquire 3,085 shares of common stock at an exercise price of $5.94 per share. Following this transaction, his direct ownership in the company is 105,135 shares, which includes shares associated with restricted stock units and those held jointly with his spouse. The options exercised were part of a grant that began vesting in October 2018 over a three-year period.
SiBone (NASDAQ:SIBN) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given SiBone (NASDAQ:SIBN) a "Moderate Buy" consensus rating, with an average 12-month price target of $24.67. Insider selling by CEO Laura Francis and other insiders has been noted, although institutional ownership remains high at 98.11%. The company recently exceeded EPS estimates and saw its revenue align with projections.
Si-Bone CFO Maheshwari sells $42,707 in stock
Anshul Maheshwari, CFO of SI-Bone, Inc. (NASDAQ:SIBN), sold 3,318 shares of company stock for $42,707 on April 2, 2026. These sales were not discretionary but were made to cover tax obligations related to the vesting of restricted stock units. Despite an overall 33% decline year-to-date, the stock has recently shown a 6.8% gain over the past week, and analysts maintain positive ratings following strong Q4 2025 financial results.
Tax-driven share sale by SI-BONE (SIBN) chief legal officer
Michael A. Pisetsky, SI-BONE's SVP and Chief Legal Officer, sold 3,134 shares of common stock on April 1-2 to cover tax withholding obligations associated with vesting restricted stock units. These "sell to cover" transactions were not discretionary trades, with sale prices ranging from $12.55 to $13.09 per share. Following these sales, Pisetsky holds 282,840 shares directly, including 151,034 shares issuable from restricted stock units.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a promising medtech innovator focusing on sacroiliac (SI) joint dysfunction, a common cause of chronic lower back pain. The article suggests that SI-BONE's minimally invasive iFuse system positions it as a leader in an underserved market with high growth potential. Investors are encouraged to consider SI-BONE for its niche specialization, strong clinical data, and increasing market adoption, despite risks like reimbursement variability and competition.
SI-BONE Inc stock: Why this medtech innovator could reshape spine surgery
SI-BONE Inc. is highlighted as a medical technology innovator focusing on sacroiliac (SI) joint dysfunction, an often-overlooked cause of chronic low back pain. The company's minimally invasive iFuse system for SI joint fusion offers a unique solution in the orthopedic market, positioning it as a leader in an underserved niche. Investors are urged to consider SI-BONE for its growth potential, strong market opportunity, and robust financial health, despite typical medtech investment risks.
